Prothena Sees Potential In Targeting Amyloid, Validated By Biogen
CEO Gene Kinney Describes Company’s Emerging Alzheimer’s Programs
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
